Centene price target raised to $158 from $146 at Oppenheimer

Oppenheimer analyst Michael Wiederhorn raised his price target for Centene to $158 from $146 given the company’s continued bullish prospects. The analyst believes the company remains well-positioned due to stable cost-trend and the potential for growth in the coming years, particularly in the Medicare and Exchange businesses. Furthermore, the recent integration of the Fidelis deal remains on track, and the additional accretion/synergies should drive incremental earnings growth in 2019 and beyond, he contends. Wiederhorn reiterates an Outperform rating on the shares.
https://thefly.com/landingPageNews.php?id=2798361